



- (51) **International Patent Classification:**  
*C07K 16/24* (2006.01) *A61K 39/395* (2006.01)
- (21) **International Application Number:**  
PCT/US2023/068621
- (22) **International Filing Date:**  
16 June 2023 (16.06.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/353,367 17 June 2022 (17.06.2022) US  
63/462,822 28 April 2023 (28.04.2023) US  
63/469,167 26 May 2023 (26.05.2023) US
- (71) **Applicant:** APOGEE BIOLOGICS, INC. [US/US]; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).
- (72) **Inventors:** SHAHEEN, Hussam H.; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). THOMPSON, Kenneth Evan; 221 Crescent St.,

Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). HARWIN, Peter; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). KISE-LAK, Tomas; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).

- (74) **Agent:** GUSTAFSON, Megan; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th Fl., Boston, Massachusetts 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (54) **Title:** ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE




FIG. 1

(57) **Abstract:** Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.

[Continued on next page]

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*